Trials / Recruiting
RecruitingNCT07215663
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- Candid Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus
Detailed description
This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of cizutamig in patients with Systemic Lupus Erythematosus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cizutamig | Cizutamig will be dosed according to the protocol |
Timeline
- Start date
- 2025-09-04
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
- First posted
- 2025-10-10
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07215663. Inclusion in this directory is not an endorsement.